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Adrenal incidentalomas (AI) are not associated, by definition,
with clinically evident syndromes; however, some AI patients
may show biochemical indexes of subclinical hypercorti-
solism (SH). Previous data on female AI patients indicated
that SH may lead to bone loss, at least at spine. No data are
available on bone involvement in samples of only AI male
patients.
We measured bone metabolism and bone mineral density at
spine and femur by dual-energy x-ray absorptiometry in 38
consecutive eugonadal male AI patients and 38 healthy
matched control subjects. Patients were subdivided accord-
ing to the presence or absence of SH (group SH and group
SH, respectively). Mean Z-score levels of spinal bone mineral
density measured by dual-energy x-ray absorptiometry were
lower (P < 0.05) in group SH (0.42  1.62) in comparison
with group SH (0.6  1.13) and controls (0.47  1.06). Thus,
in order for the most appropriate management to be individ-
ually tailored, bone mass evaluation is strongly indicated in
AI male patients with SH, irrespective of their gonadal status.
(J Clin Endocrinol Metab 87: 5491–5494, 2002)
IN RECENT YEARS, incidentally discovered adrenalmasses [adrenal incidentalomas (AI)] have been diag-
nosed with increasing frequency due to the widespread use
of abdominal imaging techniques (1–4). Among all such
lesions, adrenal cortical adenomas are the most frequent
histologic type. Although, by definition, AI patients do not
show evident clinical signs, some of these subjects may show
abnormalities of cortisol hypersecretion [subclinical hyper-
cortisolism (SH); Refs.5–13], which has been defined as a
mild autonomous cortisol excess detectable biochemically as
functional abnormalities of the hypothalamic-pituitary-
adrenal (HPA) axis (5, 6). As suggested by the Italian Study
Group on Adrenal Tumors (6), to diagnose SH, at least two
abnormalities of the HPA axis function should be present in
the absence of evident clinical signs of hormone excess. SH
may lead to clinical complications including, among others,
osteoporosis, which has been reported in female patients
(14–19).
Whether male AI patients may also suffer from osteopo-
rosis is presently unknown. This lack of knowledge is not a
trivial one: reduced bone mineral density (BMD) would,
indeed, be relevant, when addressing the clinical manage-
ment of these patients.
The aim of this cross-sectional study was to investigate
data on bone turnover and mass of different skeletal sites in
38 consecutive male AI patients, compared with those ob-
tained in 38 healthy matched controls.
Subjects and Methods
Subjects
Thirty-eight consecutive male patients with AI were enrolled from
January 1999 to June 2000 in two referral Italian centers. Diagnosis of AI
was based on the detection of a unilateral adrenal mass by noninvasive
imaging methods of the abdomen, performed invariably for unrelated
diseases (aspecific symptoms, abdominal and back pain), and the lack
of overt signs and/or symptoms of hormonal hypersecretion. We en-
rolled only male subjects to avoid gender-related confounding effects on
the skeleton (20). All patients were eugonadal, with testosterone levels
above 8.7 nmol/liter, the cut-off value of international normal references
(21).
Patients were divided into group SH (n 13) and group SH (n
25). The diagnosis of SH was based on the presence of two out of the
following three alterations of HPA axis: 1) increased urinary free cortisol
(UFC) levels (193.1 nmol/24 h), the cut-off of both our own and
international (22) normal reference values; 2) unsuppressed serum cor-
tisol levels after 1-mg overnight dexamethasone (Dex) suppression test
(serum cortisol after Dex  82.8 nmol/liter); and 3) low ACTH levels
(2.2 pmol/liter). Groups SH and SH were not different as far as
age, body mass index (BMI), and testosterone levels were concerned
(Table 1).
No subject had evidence of metastatic disease. At computed tomog-
raphy, all lesions were homogeneous, hypodense, and well shaped;
these features are consistent with the diagnosis of adrenocortical ade-
noma (4). The diameter of incidentalomas was not different between
group SH and group SH (mean sd, 3.4 1.1 vs. 2.8 0.9 cm; range,
1.0–5.0 and 1.5–5.0 cm, respectively). Six patients who displayed AI
diameters of at least 4 cm had previously refused surgery and were sent
to our departments by surgeons from other hospitals to study their
hormonal status. Pheochromocytoma and aldosteronoma were ex-
cluded by appropriate hormonal measurements (24-h urinary cat-
Abbreviations: AI, Adrenal incidentaloma(s); BGP, bone GLA pro-
tein; BMD, bone mineral density; BMI, body mass index; Cr, creatinine;
Dex, dexamethasone; D-Pyr, deoxypyridinoline; DXA, dual-energy x-
ray absorptiometry; FN, femoral neck; HPA, hypothalamic-pituitary-
adrenal; SH, subclinical hypercortisolism; UFC, urinary free cortisol.
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echolamines and plasma renin activity and aldosterone in recumbent
position and after 3 h of upright position).
Thirty-eight healthy men recruited among the clinics’ staff
and matched for age, BMI, and testosterone levels served as controls
(Table 1).
None of the 76 subjects were under any treatment or were affected
by diseases known to interfere with skeletal or mineral metabolism.
Vertebral fractures were excluded by lateral x-ray of the spine in all
cases. All subjects had normal kidney and liver functions and gave their
witnessed informed consent before entering the study, for which the
design was approved by local Ethical Committee and in accordance with
the Helsinki Declaration II.
Methods
Serum and urinary samples were collected and stored at 70 C until
assayed. In all patients, ACTH (mean of three determinations at 20-min
intervals) and cortisol were measured at 0800 h. Serum cortisol and UFC
levels (after dichloromethanol extraction) were determined immuno-
fluorimetrically by TDX-FLX kits (Abbott GmbH Diagnostika, Wiesba-
den-Delkenheim, Germany); serum ACTH levels were measured by
immunoradiometric analysis (BRAHMS Diagnostica GmbH, Berlin,
Germany).
In all patients and controls, serum intact PTH levels were measured
by a two-site immunochemiluminometric assay (Chiron Corp., East
Walpole, MA), and testosterone levels were measured by RIA (Byk-
Sangtec Diagnostica GmbH & Co. KG, Dietzenbach, Germany). In 23
patients and 23 controls, the following markers of bone turnover were
assayed: serum bone GLA protein (BGP) by immunoradiometric anal-
ysis for the intact molecule (ELSA-OST-NAT, Cis Biointernational,
Gif-sur-Yvette, France; intra- and interassay coefficients of variation,
3.8% and 4.7%, respectively), and total deoxypyridinoline on fasting spot
urine corrected for creatinine excretion (D-Pyr/Cr) after reverse phase
HPLC, fluorometrically by Bio-Rad Laboratories, Inc. kits (Segrate-
Milano, Italy; intra- and interassay coefficients of variation, 6.6% and
12.3%, respectively).
In all patients and controls, BMD was evaluated by dual-energy x-ray
absorptiometry (DXA; Norland XR-26; Norland Instruments, Fort At-
kinson, WI) at the following skeletal sites: spine (DXA L2–L4, in vivo
precision, 1.0%) and femoral neck (FN; in vivo precision, 2.3%). Indi-
vidual BMD values were expressed as sd units (Z-values) in relation to
reference population of our center (23). Osteoporosis and osteopenia
were diagnosed according to World Health Organization criteria (24).
Statistical analysis
The results are expressed as mean sd. For each variable, normality
of distribution was tested by the W statistic of Shapiro-Wilk. Data were
compared by Student’s t test, Mann-Whitney U test, or one-way
ANOVA test and Student-Newman-Keuls test post hoc analysis, as ap-
propriate. A 2 test was used to evaluate the difference in the ratio of
osteopenic and osteoporotic patients between subgroups. The associa-
tions between variables were tested by either Pearson or Spearman
correlation, as appropriate. Probability values of less than 0.05 were
considered significant.
Results
Individual hormonal and BMD data are shown in Table 2.
Markers of disease activity in the two groups (SH and
SH) are shown in Table 3.
BGP and PTH levels were similar in group SH, group
SH, and controls (Table 3). Mean D-Pyr/Cr levels were
nearly twice as high in SH vs. SH or control subjects, but
statistical significance was not reached, due to the wide vari-
ability of the values.
Mean BMD Z-score measured at lumbar spine was sig-
nificantly lower in group SH than in group SH and con-
trols (Table 3). Thus, the prevalence of osteoporosis and
osteopenia was significantly higher in group SH than in
group SH [11 of 13 (84.6%) vs. 9 of 25 (36.0%); 2 6.28; P
0.01]. Taking into account BMD at FN, mean Z-values were
lower in group SH than in group SH or controls, but this
difference did not reach statistical significance, due to the
wide range of distribution of the values (Table 3).
Finally, no correlation was found between UFC, ACTH,
serum cortisol after Dex with BGP, D-Pyr/Cr, or BMD Z-
values measured at each site.
Discussion
To the best of our knowledge, this is the first report of bone
involvement in a sample of consecutive AI male patients. We
demonstrated that patients with biochemical SH (group
SH) have reduced spinal BMD and a higher rate of
osteopenia/osteoporosis compared with AI patients without
SH and healthy control subjects (Table 3).
We did not observe changes in BGP levels related to the
degree of cortisol secretion; this is at variance with our pre-
vious cross-sectional study on female AI patients (15). This
apparent discrepancy may well be due to the milder degree
of cortisol hypersecretion of male AI patients with SH in the
present report compared with that of female AI patients with
SH in the previous report, as reflected by mean UFC level
[262.8 (range, 162.0–445.5) vs. 332.9 (range, 201.5–874.9)
nmol/24 h].
As far as bone mass is concerned, some, but not all (16),
previous data from cross-sectional studies (15, 18) and, most
importantly, a longitudinal one (19), have shown that BMD
of the spine is reduced in female AI patients with SH (25). The
present data, showing reduced spinal BMD also in male AI
patients with SH, therefore indicate that the deleterious effect
of subtle cortisol hypersecretion on bone mass is not gender
specific. In addition, because our male AI patients were all
eugonadal, these data indicate that the effect of SH on bone
mass overcomes the protective role of gonadal steroids, a
finding previously reported also in female AI patients (19).
In our opinion, this finding is of importance when consid-
ering that, compared with women, men are clearly at lower
risk of osteoporotic fracture and have higher BMD values
even when defined as osteoporotic by World Health Orga-
nization criteria (26).
TABLE 1. Clinical characteristics of patients and controls
Controls (n  38)
Patients
Group SH (n  25) Group SH (n  13)
Age (yr) 56.9  11.8 (26–74) 55.2  12.6 (21–78) 61.4  11.3 (40–75)
BMI (kg/m2) 26.9  2.6 (21.3–32.1) 27.2  3.0 (21.5–32.9) 27.1  3.0 (23.2–31.9)
Height (m) 1.70  0.09 (1.55–1.88) 1.67  0.08 (1.55–1.86) 1.69  0.06 (1.58–1.77)
Testosterone (nmol/liter) 14.8  3.8 (10.4–24.9) 16.7  4.6 (11.4–26.0) 14.6  4.4 (10.4–24.3)
Data are mean  SD (range in parentheses). No statistically significant differences were found between each group of patients and controls
for each parameter.
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In our series of AI male patients, bone mass at FN was
reduced, although not significantly, in group SH when
compared with group SH and controls (Table 3). This lack
of significance observed in the present study on male patients
could be explained by the wide range of distribution of BMD
FN values and the relatively small sample size studied.
In conclusion, our data indicate a deleterious effect of
subclinical endogenous cortisol excess on bone in male AI
patients, despite their normal gonadal status. Although cau-
tion is needed because of the cross-sectional design of the
study, BMD evaluation is advisable in AI male patients who
have evidence of subtle cortisol hypersecretion. However,
further longitudinal studies are needed to better clarify this
issue.
TABLE 2. Biochemical parameters of adrenal function and BMD Z-scores in patients with AI
Patient no. UFC(nmol/24 h)
ACTH
(pmol/liter)
F after Dex
(nmol/liter) Z-DXA Z-FN SH
1 89.7 2.2 24.8 0.080 1.100 
2 99.4 5.1 35.9 0.020 0.120 
3 104.9 3.3 41.4 0.100 0.400 
4 106.3 3.3 60.7 0.740 0.900 
5 118.7 4.6 52.4 1.470 3.210 
6 123.1 3.6 55.2 1.750 1.290 
7 124.5 2.8 35.9 2.160 0.620 
8 131.1 3.2 35.9 0.370 0.400 
9 132.5 4.5 66.2 1.130 0.790 
10 135.2 2.6 96.6 0.700 0.940 
11 138.0 2.0 24.8 2.090 1.980 
12 144.1 5.1 44.2 2.610 0.440 
13 147.7 2.3 35.9 0.670 0.230 
14 151.2 4.2 22.1 1.750 1.180 
15 151.8 3.3 69.0 0.780 0.340 
16 154.6 5.7 69.0 0.960 0.280 
17 155.1 3.3 44.2 0.820 0.940 
18 163.1 3.1 49.7 0.890 0.860 
19 163.4 10.3 13.8 0.340 1.050 
20 169.5 6.0 110.4 2.260 0.750 
21 175.8 6.4 35.9 0.870 0.630 
22 192.9 6.4 71.8 0.270 1.360 
23 238.7 4.3 27.6 1.500 1.350 
24 320.2 2.4 73.1 0.890 0.740 
25 361.8 2.2 58.0 0.550 2.100 
26 162.0 0.7 140.8 2.760 2.660 
27 201.5 2.0 113.2 2.600 1.660 
28 203.1 0.5 91.1 1.710 0.270 
29 218.0 3.1 82.8 0.700 0.600 
30 220.2 1.8 69.0 1.950 0.120 
31 248.4 1.4 58.0 1.170 0.470 
32 258.9 1.1 132.5 1.400 1.000 
33 273.2 1.5 193.2 1.200 0.400 
34 273.2 2.2 99.4 1.800 0.400 
35 278.8 2.0 143.5 0.120 2.110 
36 303.6 10.6 82.8 0.600 0.600 
37 328.2 3.8 82.8 1.560 0.350 
38 445.5 2.0 85.6 1.150 0.340 
UFC, Normal values less than 193.1 nmol/24 h; ACTH, mean of three determinations at 0800 h, normal values above 2.2 pmol/liter; F after
Dex, serum cortisol at 0800 h after 1 mg overnight Dex, normal values less than 82.8 nmol/liter; Z-DXA L2–L4, lumbar vertebral integral spine
L2–L4 BMD as Z-values; Z-FN, FN BMD as Z-values.
TABLE 3. Biochemical indexes of bone turnover and BMD Z-scores in patients and controls
Controls (n  38)
Patients
Group SH (n  25) Group SH (n  13)
UFC (nmol/24h) 159.7  63.2 (89.7–361.8) 262.8  71.4b (162.0–445.5)
ACTH (pmol/liter) 4.1  1.87 (2.0–10.3) 2.5  2.6b (0.5–10.6)
F after Dex (nmol/liter) 49.7  23.5 (13.8–110.4) 105.7  38.6b (58.0–193.2)
BGP (pmol/liter) 3.9  1.2 (2.1–6.3) 2.8  0.7 (1.6–3.9) 3.2  1.0 (2.0–5.1)
Urinary D-Pyr/Cr (pmol/pmol) 12.7  4.7 (5.8–22.6) 13.5  5.9 (6.7–26.1) 23.2  21.5 (8.2–69.8)
PTH (ng/liter) 40.9  13.8 (22.4–81.2) 40.3  12.3 (21–65) 38.5  10.6 (20.8–61.3)
DXA L2–L4 (Z-values) 0.47  1.06 (1.00–2.47) 0.60  1.13 (1.75–2.61) 0.42  1.62a (2.6–2.76)
FN BMD (Z-values) 0.49  1.11 (1.03–2.88) 0.70  0.95 (1.18–3.21) 0.02  1.19 (1.66–2.66)
Data are mean  SD (range in parentheses). DXA L2–L4, Lumbar vertebral integral spine L2–L4 BMD.
a P  0.05 vs. group SH and controls.
b P  0.0001 vs. group SH.
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